Part 1, Reference for Chapter 12: Adverse Immunological Reactions to Drugs
Skip chapter table of contents and go to main content
- 1 Small anti‐viral compounds activate immune cells via the TLR7 MyD88‐dependent signaling pathway. Nat Immunol 2002;3(2):196–200. Cross Ref link Pubmed link , , , et al.
- 2 Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: GellRR, ed. Clinical Aspects of Immunology. Oxford: Oxford University Press, 1968:575–96. , .
- 3 Role of mast cells in allergic and non‐allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007;7(2):93–104. Cross Ref link Pubmed link .
- 4 Polymorphisms and haplotype analysis of IL‐4Ralpha Q576R and I75V in patients with penicillin allergy. Eur J Clin Pharmacol 2009;65(9):895–902. Cross Ref link Pubmed link , , , .
- 5 Relationships between specific serum IgE, cytokines and polymorphisms in the IL‐4, IL‐4Ralpha in patients with penicillins allergy. Allergy 2005;60(8):1053–9. Cross Ref link Pubmed link , , .
- 6 Specific serum IgE levels and FcepsilonRIbeta genetic polymorphism in patients with penicillins allergy. Allergy 2004;59(12):1326–32. Cross Ref link Pubmed link , , .
- 7 Gene–gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics. Pharmacogenet Genomics 2006;16(10):713–19. Cross Ref link Pubmed link , , , , , .
- 8 IL‐10 promoter and IL4‐Ralpha gene SNPs are associated with immediate beta‐lactam allergy in atopic women. Allergy 2006;61(8):921–7. Cross Ref link Pubmed link , , , , , .
- 9 Interleukin‐18 and IL18 ‐607A/C and ‐137G/C gene polymorphisms in patients with penicillin allergy. J Int Med Res 2011;39(2):388–98. Cross Ref link Pubmed link , , , .
- 10 Polymorphisms of STAT6 and specific serum IgE levels in patients with penicillin allergy. Int J Clin Pharmacol Ther 2012;50(7):461–7. Cross Ref link Pubmed link , , , .
- 11 Association of three sets of high‐affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin‐intolerant asthma. Respir Med 2008;102(8):1132–9. Cross Ref link Pubmed link , , , , , .
- 12 Tick bites and red meat allergy. Curr Opin Allergy Clin Immunol 2013;13(4):354–9. Cross Ref link Pubmed link , .
- 13 Activation of drug‐specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995;155(1):462–72. Pubmed link , , , , , .
- 14 Drug hypersensitivity reactions: classification and relationship to T‐cell activation. In: PichlerWJ, ed. Drug Hypersensitivity. Basel: Karger, 2007:168–89. Cross Ref link .
- 15 et al. Toxic epidermal necrolysis: effector cells are drug‐specific cytotoxic T cells. J Allergy Clin Immunol 2004;114(5):1209–15. Cross Ref link Pubmed link , , ,
- 16 Recurrent fatal drug‐induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta‐lactam cross‐reactivity: case report and scrutiny of antibiotic imputability. Crit Care Med 2002;30(11):2580–3. Cross Ref link Pubmed link , , , .
- 17 Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2013;67(11):1338–46. Cross Ref link , , , .
- 18 Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282(5388):490–3. Cross Ref link Pubmed link , , , et al.
- 19 Toxic epidermal necrolysis and Stevens–Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162(5):1515–20. Cross Ref link Pubmed link , , , , , .
- 20 Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug‐induced toxic epidermal necrolysis. Arch Dermatol Res 2005;297(6):266–73. Cross Ref link Pubmed link , , , , .
- 21 Immunohistochemical expression of apoptotic markers in drug‐induced erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol 2007;20(3):557–66. Pubmed link , , , et al.
- 22 Soluble FAS ligand: a discriminating feature between drug‐induced skin eruptions and viral exanthemas. J Invest Dermatol 2007;127(4):802–7. Cross Ref link Pubmed link , , .
- 23 Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14(12):1343–50. Cross Ref link Pubmed link , , , et al.
- 24 TNF‐alpha and IFN‐gamma are potential inducers of Fas‐mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 2013;133(2):489–98. Cross Ref link Pubmed link , , , et al.
- 25 Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995;131(5):544–51. Cross Ref link Pubmed link , , , , , .
- 26 The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154(2):319–24. Cross Ref link Pubmed link , , , et al.
- 27 Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154(5):1006–7. Cross Ref link Pubmed link , , , et al.
- 28 Drug specific cytotoxic T‐cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002;118(4):728–33. Cross Ref link Pubmed link , , , et al.
- 29 Soluble fractions of tumor necrosis factor‐alpha, interleukin‐6 and of their receptors in toxic epidermal necrolysis: a comparison with second‐degree burns. Int J Mol Med 1998;1(2):459–62. Pubmed link , .
- 30 Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123(5):850–5. Cross Ref link Pubmed link , , , et al.
- 31 Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352(9140):1586–9. Cross Ref link Pubmed link , , , et al.
- 32 Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 2009;36(3):150–3. Cross Ref link Pubmed link , , , , .
- 33 Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol 2008;88(4):420–1. Pubmed link , , , , , .
- 34 Antitumour necrosis factor‐alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146(4):707–9. Cross Ref link Pubmed link , , , .
- 35 Rapid resolution of toxic epidermal necrolysis with anti‐TNF‐alpha treatment. J Allergy Clin Immunol 2005;116(4):923–4. Cross Ref link Pubmed link , , , , .
- 36 Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156(3):609–11. Cross Ref link Pubmed link , , , et al.
- 37 The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007;156(5):1083–4. Cross Ref link Pubmed link , , , .
- 38 The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59(8):809–20. Cross Ref link Pubmed link , .
- 39 In vitro diagnostic assays are effective during the acute phase of delayed‐type drug hypersensitivity reactions. Br J Dermatol 2013;168(3):539–49. Cross Ref link Pubmed link , , , et al.
- 40 Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998;134(9):1113–17. Cross Ref link Pubmed link , , , et al.
- 41 Human herpesvirus 6 infection as a risk factor for the development of severe drug‐induced hypersensitivity syndrome. Arch Dermatol 1998;134(9):1108–12. Cross Ref link Pubmed link , , , , .
- 42 Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137(3):301–4. Pubmed link , , , et al.
- 43 DRESS syndrome associated with HHV‐6 reactivation. Eur J Intern Med 2003;14(8):498–500. Cross Ref link Pubmed link , , .
- 44 Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010;2(46):46–62. Cross Ref link , , , et al.
- 45 Association of human herpesvirus 6 reactivation with the flaring and severity of drug‐induced hypersensitivity syndrome. Br J Dermatol 2007;157(5):934–40. Cross Ref link Pubmed link , , , et al.
- 46 The predominant drug‐specific T‐cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant‐induced hypersensitivity. J Dermatol Sci 2012;65(3):213–19. Cross Ref link Pubmed link , , , .
- 47 T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci 2007;48(1):25–33. Cross Ref link Pubmed link , , , .
- 48 Acute generalized exanthematous pustulosis due to sulfamethoxazol with positive lymphocyte transformation test (LTT). J Invest Allergol Clin Immunol 2003;13(1):66–8. , .
- 49 Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 2004;173(3):2151–8. Cross Ref link Pubmed link , , , et al.
- 50 Cross‐comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. Am J Dermatopathol 2005;27(4):343–6. Cross Ref link Pubmed link , , , , , .
- 51 T‐cell involvement in drug‐induced acute generalized exanthematous pustulosis. J Clin Invest 2001;107(11):1433–41. Cross Ref link Pubmed link , , , et al.
- 52 Increased circulating Th17 frequencies and serum IL‐22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol 2011;25(4):485–8. Cross Ref link Pubmed link , , , , , .
- 53 Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009;9(4):316–21. Cross Ref link Pubmed link .
- 54 Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab‐treated CTCL patients. Sci Transl Med 2012;4(117):117ra7. Cross Ref link Pubmed link , , , et al.
- 55 Skin infection generates non‐migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012;483(7388):227–31. Cross Ref link Pubmed link , , , , , .
- 56 Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol 1988;27(3):170–4. Cross Ref link Pubmed link , .
- 57 Clinical resemblance of widespread bullous fixed drug eruption to Stevens–Johnson syndrome or toxic epidermal necrolysis: report of two cases. J Formos Med Assoc 2002;101(8):572–6. Pubmed link , , .
- 58 Prognosis of generalized bullous fixed drug eruption: comparison with Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2013;168(4):726–32. Cross Ref link Pubmed link , , , et al.
- 59 Drug‐induced immune thrombocytopenia. N Engl J Med 2007;357(6):580–7. Cross Ref link Pubmed link , .
- 60 Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992;34(5):377–95. Cross Ref link Pubmed link , , .
- 61 Immunologic mechanisms of cutaneous drug reactions. Semin Cutan Med Surg 1996;15(4):228–35. Cross Ref link Pubmed link , .
- 62 T cell antigen receptor genes and T cell recognition. Nature 1988;334(395):395–402. Cross Ref link Pubmed link , .
- 63 A direct estimate of the human alphabeta T cell receptor diversity. Science 1999;286(5441):958–61. Cross Ref link Pubmed link , , , , , .
- 64 Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988;245(3):1103–9. Pubmed link , , , .
- 65 Antibody assays for the detection of patients sensitized to halothane. Anesth Analg 1990;70(2):154–9. Cross Ref link Pubmed link , , .
- 66 Epitope mapping studies with human anti‐cytochrome P450 3A antibodies. Mol Pharmacol 1996;49(2):234–43. Pubmed link , , , .
- 67 The danger model: a renewed sense of self. Science 2002;296(5566):301–5. Cross Ref link Pubmed link .
- 68 Danger” conditions increase sulfamethoxazole‐protein adduct formation in human antigen‐presenting cells. J Pharmacol Exp Ther 2009;331(2):372–81. Cross Ref link Pubmed link , , , , . “
- 69 Rapid and preferential activation of the c‐jun gene during the mammalian UV response. Mol Cell Biol 1991;11(5):2804–11. Cross Ref link Pubmed link , , , .
- 70 A role for oxygen radicals as second messengers. Trends Cell Biol 1991;1(2–3):39–42. Cross Ref link Pubmed link , .
- 71 Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF‐kappa B transcription factor and HIV‐1. EMBO J 1991;10(8):2247–58. Pubmed link , , .
- 72 Transcription factor Nrf2 coordinately regulates a group of oxidative stress‐inducible genes in macrophages. J Biol Chem 2000;275(21):16023–9. Cross Ref link Pubmed link , , , et al.
- 73 The Nrf2‐antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009;284(20):13291–5. Cross Ref link Pubmed link , , .
- 74 Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004;16(6):732–7. Cross Ref link Pubmed link , .
- 75 Direct T‐cell stimulations by drugs – bypassing the innate immune system. Toxicology 2005;209(2):95–100. Cross Ref link Pubmed link .
- 76 High sensitivity of human leukocyte antigen‐b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46(7):1111–18. Cross Ref link Pubmed link , , , et al.
- 77 HLA‐B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102(11):4134–9. Cross Ref link Pubmed link , , , et al.
- 78 Genetic susceptibility to carbamazepine‐induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16(4):297–306. Cross Ref link Pubmed link , , , et al.
- 79 Immune self‐reactivity triggered by drug‐modified HLA‐peptide repertoire. Nature 2012;486(7404):554–8. Pubmed link , , , et al.
- 80 Drug hypersensitivity caused by alteration of the MHC‐presented self‐peptide repertoire. Proc Natl Acad Sci USA 2012;109(25):9959–64. Cross Ref link Pubmed link , , , et al.
- 81 HLA‐B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568–79. Cross Ref link Pubmed link , , , et al.
- 82 The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24(10):1502–14. Cross Ref link Pubmed link .
- 83 Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23(10):1603–14. Cross Ref link Pubmed link , , , et al.
- 84 Pharmacogenomics of severe cutaneous adverse reactions and drug‐induced liver injury. J Hum Genet 2013;58(6):317–26. Cross Ref link Pubmed link , .
- 85 Predisposition to abacavir hypersensitivity conferred by HLA‐B*5701 and a haplotypic Hsp70‐Hom variant. Proc Natl Acad Sci USA 2004;101(12):4180–5. Cross Ref link Pubmed link , , , et al.